- Germany has signed a contract with CureVac BV (NASDAQ:CVAC) and its partner GlaxoSmithKline plc (NYSE:GSK) for domestically produced mRNA vaccines to bolster supplies for pandemic preparedness.
- The five-year contract allows for the production of up to 80 million doses at short notice until 2029, CureVac said, adding that those doses could be for the remainder of the current pandemic or future outbreaks.
- CureVac gave up on its first-generation COVID-19 vaccine candidate, CVnCoV, last year after poor data, but trials for the next-generation COVID-19 shots have begun.
- Related: CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial.
- Under the contract, the federal government will pay CureVac and GSK an annual standby fee after completing the setup period, which requires the companies to maintain manufacturing capacity at constant readiness.
- Price Action: CVAC shares are down 2.66% at $17.22, and GSK stock is down 0.40% at $46.46 during the market session on the last check Monday.
